Figure 6.
MYST1 overexpression promotes GBM progression and upregulates EGFR signaling pathway. A, Western blots of proteins expression in EGFR signaling pathways in LN229 and U87 cells after MYST1/GFP overexpression. B, qRT‐PCR analysis of EGFR mRNA expression after MYST1 overexpression. C, MTT assay reveals significant cell proliferation promotion induced by MYST1/GFP overexpression in LN229 and U87 cells (n = 3). D and E, The effect of MYST1/GFP silencing on tumorigenicity in BALB/c‐nu nude mice. LN229 and U87 cells with MYST1/GFP overexpression were injected subcutaneously into the nude mice (n = 4). Tumor burden was monitored every 4 d by a digital caliper. Tumor size was calculated as the formula: length × width2 × π/6. After the experiment, mice were sacrificed and the tumor was taken out and weighted. F, Western blots of proteins expression in EGFR signaling pathways in indicated tumors obtained from the nude mice. All data were used as mean ± SD, n ≥ 3, significant difference was tested by STUDENT's t test. **P < .01, ***P < .001. P < .05 was considered as statistically significant. EGFR, epidermal growth factor receptor; GBM, glioblastoma; GFP, green fluorescent protein